World Journal of *Gastroenterology*

World J Gastroenterol 2024 February 28; 30(8): 779-993





Published by Baishideng Publishing Group Inc

WJG

World Journal of VV01111 Juni Gastroenterology

Contents

Weekly Volume 30 Number 8 February 28, 2024

EDITORIAL

- 779 Immunotherapy of gastric cancer: Present status and future perspectives Triantafillidis JK, Konstadoulakis MM, Papalois AE
- 794 Immune signature of small bowel adenocarcinoma and the role of tumor microenvironment Christodoulidis G, Kouliou MN, Koumarelas KE
- 799 Management of autoimmune hepatitis induced by hepatitis delta virus Gigi E, Lagopoulos V, Liakos A
- 806 Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era Zhong JH

OPINION REVIEW

811 Nonsteroidal anti-inflammatory drugs before endoscopic ultrasound guided tissue acquisition to reduce the incidence of post procedural pancreatitis

de Jong M, van Delft F, Roozen C, van Geenen EJ, Bisseling T, Siersema P, Bruno M

REVIEW

817 Autoimmune pancreatitis: Cornerstones and future perspectives

Gallo C, Dispinzieri G, Zucchini N, Invernizzi P, Massironi S

MINIREVIEWS

833 Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect

Qiu XX, Cheng SL, Liu YH, Li Y, Zhang R, Li NN, Li Z

ORIGINAL ARTICLE

Retrospective Study

843 Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus

Wu HX, Ding XY, Xu YW, Yu MH, Li XM, Deng N, Chen JL

855 Immunoglobulin G-mediated food intolerance and metabolic syndrome influence the occurrence of reflux esophagitis in Helicobacter pylori-infected patients

Wang LH, Su BB, Wang SS, Sun GC, Lv KM, Li Y, Shi H, Chen QQ

863 Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor

Deng GM, Song HB, Du ZZ, Xue YW, Song HJ, Li YZ



Contents

World Journal of Gastroenterology

Weekly Volume 30 Number 8 February 28, 2024

Observational Study

881 Mitochondrial dysfunction affects hepatic immune and metabolic remodeling in patients with hepatitis B virus-related acute-on-chronic liver failure

Zhang Y, Tian XL, Li JQ, Wu DS, Li Q, Chen B

Basic Study

Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular 901 carcinoma

Wang YY, Shen MM, Gao J

919 Lipid metabolism-related long noncoding RNA RP11-817I4.1 promotes fatty acid synthesis and tumor progression in hepatocellular carcinoma

Wang RY, Yang JL, Xu N, Xu J, Yang SH, Liang DM, Li JZ, Zhu H

SYSTEMATIC REVIEWS

943 Quality of life after pancreatic surgery Li SZ, Zhen TT, Wu Y, Wang M, Qin TT, Zhang H, Qin RY

META-ANALYSIS

956 Prevalence and clinical impact of sarcopenia in liver transplant recipients: A meta-analysis

Jiang MJ, Wu MC, Duan ZH, Wu J, Xu XT, Li J, Meng OH

SCIENTOMETRICS

969 Bibliometrics analysis based on the Web of Science: Current trends and perspective of gastric organoid during 2010-2023

Jiang KL, Jia YB, Liu XJ, Jia QL, Guo LK, Wang XX, Yang KM, Wu CH, Liang BB, Ling JH

CASE REPORT

984 Cronkhite-Canada syndrome with esophagus involvement and six-year follow-up: A case report Tang YC

LETTER TO THE EDITOR

991 Monitoring of hepatocellular carcinoma Akkari I, Jaziri H



Contents

Weekly Volume 30 Number 8 February 28, 2024

ABOUT COVER

Editorial Board Member of World Journal of Gastroenterology, Neal Shahidi, MD, FRCPC, PhD, Assistant Professor, Department of Medicine, Division of Gastroenterology, St Paul's Hospital, Vancouver V6Z 2K5, British Columbia, Canada. nshahidi@providencehealth.bc.ca

AIMS AND SCOPE

The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yu-Xi Chen, Production Department Director: Xiang Li, Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Gastroenterology	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 1007-9327 (print) ISSN 2219-2840 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
October 1, 1995	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Weekly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Andrzej S Tarnawski	https://www.wjgnet.com/bpg/gerinfo/208
EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF	Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou- Bao Liu (Biliary Tract Disease)
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
http://www.wjgnet.com/1007-9327/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
February 28, 2024	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2024 Baishideng Publishing Group Inc	https://www.f6publishing.com
PUBLISHING PARTNER	PUBLISHING PARTNER'S OFFICIAL WEBSITE
Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University Biliary Tract Disease Institute, Fudan University	https://www.shca.org.cn https://www.zs-hospital.sh.cn

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



WU

World Journal of *Gastroenterology*

Submit a Manuscript: https://www.f6publishing.com

World J Gastroenterol 2024 February 28; 30(8): 806-810

DOI: 10.3748/wjg.v30.i8.806

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

EDITORIAL

Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era

Jian-Hong Zhong

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Jackson T, United States

Received: December 10, 2023 Peer-review started: December 10, 2023 First decision: December 27, 2023 Revised: December 27, 2023 Accepted: January 31, 2024 Article in press: January 31, 2024

Published online: February 28, 2024



Jian-Hong Zhong, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi Zhuang Autonomous Region, China

Corresponding author: Jian-Hong Zhong, Doctor, PhD, Academic Editor, Doctor, Professor, Surgeon, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. zhongjianhong@gxmu.edu.cn

Abstract

Approximately 50%-70% of patients with hepatocellular carcinoma experience recurrence within five years after curative hepatic resection or ablation. As a result, many patients receive adjuvant therapy after curative resection or ablation in order to prolong recurrence-free survival. The therapy recommended by national guidelines can differ, and guidelines do not specify when to initiate adjuvant therapy or how long to continue it. These and other unanswered questions around adjuvant therapies make it difficult to optimize them and determine which may be more appropriate for a given type of patient. These questions need to be addressed by clinicians and researchers.

Key Words: Adjuvant therapy; Hepatocellular carcinoma; Tumor recurrence; Unanswered questions

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Several questions need to be addressed by clinical researchers about the use of adjuvant therapy to prolong recurrence-free survival of patients with hepatocellular carcinoma following potentially curative treatment.

Citation: Zhong JH. Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era. *World J Gastroenterol* 2024; 30(8): 806-810 **URL**: https://www.wjgnet.com/1007-9327/full/v30/i8/806.htm **DOI**: https://dx.doi.org/10.3748/wjg.v30.i8.806

Raishideng® WJG | https://www.wjgnet.com

INTRODUCTION

Primary or recurrent hepatocellular carcinoma (HCC) in certain patients can be treated through potentially curative hepatic resection or local ablation[1,2], which is typically defined as complete resection of the tumor, return of alpha fetoprotein levels to normal, and no sign of recurrence 4-8 wk later on contrast-enhanced computed tomography or magnetic resonance imaging[3]. Unfortunately, 50%-70% of patients experience intra- or extrahepatic metastases within five years after such procedures, and these metastases are the most frequent cause of HCC-related death[1,2]. For example, patients with primary HCC in the "very early" or "early" stages according to the Barcelona Clinic Liver Cancer staging system show 5-year recurrence rates of 40.7% after hepatectomy and 29.3% after local ablation[4], and the rate after hepatectomy falls to 18%-25% if the HCC is "intermediate" or "advanced" [5].

Therefore many patients are given adjuvant therapy after curative resection or ablation in order to prolong recurrencefree survival. However, international consensus is lacking about many aspects of adjuvant therapy, including which is the best type for a given type of patient, when it should be performed, and how long it should last. The question has even been raised whether adjuvant therapy is effective at all in certain contexts. These are important questions that need to be addressed through well-designed research and informed discussion.

Who can benefit from adjuvant therapy?

Adjuvant therapy increases treatment costs and risks of adverse events, so it should not be administered routinely to all patients whose tumors have been completely removed by resection or ablation. Instead, national guidelines recommend it for certain types of patients. The Chinese Liver Cancer staging system[3] and the American Association for the Study of Liver Diseases[1] recommend it for patients with factors associated with high risk of recurrence, such as tumor size > 5 cm, presence of > 3 tumors, micro- or macrovascular invasion, or poor tumor differentiation.

Whether these guidelines are optimal is questionable, in light of evidence identifying additional potential risk factors, such as the absence of a tumor capsule, tumor rupture, narrow resection margin (≤ 2 cm) and alpha fetoprotein ≥ 400 ng/ mL[1,3]. In addition, the risk factors in guidelines have been associated primarily with recurrence within 6 months after curative treatment, meaning that the guidelines neglect liver cirrhosis and chronic hepatitis, which have been linked primarily to late recurrence[6,7]. The evidence base for all these risk factors should be expanded to the point that they can be taken into account in future versions of guidelines. Another question that should be addressed is whether adjuvant therapy is effective for all etiologies of HCC: For example, immune checkpoint inhibitors may offer limited benefit to patients with HCC linked to non-alcoholic steatohepatitis[8].

Which adjuvant therapies work best?

Based on extensive evidence from randomized controlled trials, Chinese Liver Cancer guidelines mention several adjuvant therapies as effective: Transarterial chemoembolization, hepatic arterial infusion chemotherapy, molecular targeted drugs, and adoptive immunotherapy[3]. In contrast, guidelines from South Korea[9] and the United States[1] do not recommend adjuvant transarterial chemoembolization or hepatic arterial infusion chemotherapy, although the South Korean guidelines do recommend adoptive immunotherapy based on strong evidence, while the United States guidelines mention immune checkpoint inhibition for the first time in the latest revision. Guidelines from the United States and China, but not South Korea, recommend adjuvant antiviral therapy with tenofovir or entecavir for patients with HCC related to chronic infection with hepatitis B virus[1,3].

The evidence base for the efficacy of some adjuvant therapies remains to be solidified. Only one randomized controlled trial has explored adjuvant use of the tyrosine kinase inhibitor sorafenib[10], reporting no significant benefit on recurrence-free or overall survival relative to placebo, and randomized trials of other molecular targeted drugs are ongoing. For example, an evaluation of the adjuvant combination of atezolizumab and bevacizumab has yet to reach the endpoint of median recurrence-free survival[11], although one study suggested that the two therapeutic antibodies may synergize to inhibit tumor angiogenesis, regulatory T proliferation and myeloid cell inflammation^[12]. One study has suggested that molecular targeted drugs can potentiate adjuvant immune checkpoint blockade[11]. The current landscape of clinical evidence does not provide multiple, clearly effective treatments based on molecular targeted drugs, which makes it difficult to identify which ones may be optimal for given types of patient. Several network meta-analyses have examined the landscape but failed to converge on clear recommendations for clinical practice because of heterogeneity among patient populations and treatment protocols.

When should adjuvant therapy begin?

This is a key consideration given the inevitable side effects of adjuvant therapy, yet no major guidelines recommend a particular start time. Most randomized controlled trials initiate it 4-8 wk after curative resection. This question should be explored in clinical trials, which should consider that the optimal timing of initiation likely depends on perioperative complications, wound healing, residual liver function, and patient characteristics such as performance status and comorbidities.

How long should adjuvant therapy last?

The evidence base around immune checkpoint blockade and molecular targeted drugs does not clearly indicate minimal or maximal duration of adjuvant treatment. In one trial, sorafenib therapy was scheduled for 48 months, but it lasted closer to 12-13 months because of the lack of efficacy and high frequency of adverse events [10]. In another trial, the combination of atezolizumab and bevacizumab was scheduled for 12 months, and it lasted a median of 11 months[11]. This duration may be too long, at least for certain types of patients: Immune checkpoint inhibitor therapy for 6 months



WJG | https://www.wjgnet.com

Zhong JH. Unanswered questions about adjuvant therapy




Figure 1 Unanswered questions about adjuvant therapy for patients with hepatocellular carcinoma following potentially curative resection or local ablation. Questions appear within the pie, and evidence-based responses are written around it. AIT: Adoptive immunotherapy; HAIC: Hepatic arterial infusion chemotherapy; ICI: Immune checkpoint inhibitor; RFS: Recurrence-free survival; TACE: Transarterial chemoembolization; Vp1: Segmental portal vein invasion; Vp2: Right anterior or posterior portal vein invasion.

was sufficient to prolong recurrence-free survival in one prospective study [13], and median progression-free survival was shorter than 12 months among patients with unresectable HCC who were treated with immune checkpoint inhibitors alone or together with molecular targeted drugs[14,15].

These observations suggest that 12 months of immune checkpoint inhibition may be excessive and, in any case, that the duration of adjuvant therapy will need to be determined based on its mechanism(s) of action. The indications for transarterial therapy, molecular targeted drugs, adoptive immunotherapy and immune checkpoint inhibition were originally formulated for patients with unresectable HCC, so they may not be optimal for patients whose disease is in an early, resectable stage and who are likely to survive long enough for late recurrence to be a concern. For example, patients with resectable disease who are chronically infected with hepatitis B virus should probably continue antiviral therapy for the long term, perhaps even the rest of their lives [16-18].

CONCLUSION

The costs and adverse effects of adjuvant therapy dictate that clinical researchers better define what therapies should be administered to which patients when and for how long (Figure 1), and that the best evidence be integrated into the next versions of consensus guidelines. This task becomes more urgent as more medical centers administer molecular targeted drugs and immune checkpoint inhibitors to HCC patients[19,20]. Eventually guidelines will also need to take stock of the growing use of neoadjuvant and "conversion" therapies, which promise to make potentially curative treatment accessible to patients with traditionally unresectable HCC.

FOOTNOTES

Author contributions: Zhong JH wrote and revised the manuscript.

Supported by the Specific Research Project of Guangxi for Research Bases and Talents, No. GuiKe AD22035057; and the National Natural Science Foundation of China, No. 82060510 and No. 82260569.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China



WJG https://www.wjgnet.com

ORCID number: Jian-Hong Zhong 0000-0002-1494-6396.

S-Editor: Wang JJ L-Editor: A P-Editor: Chen YX

REFERENCES

- 1 Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023; 78: 1922-1965 [PMID: 37199193 DOI: 10.1097/HEP.00000000000466]
- 2 Federica C, Gianluca F, Margherita R, Federica P, Federica I, Andrea CG, Francesco De C, Massimo C, Luca A. Surgery for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: milestone changes in the last two decades potentially affecting current guidelines. Hepatoma Res 2023; 9: 13 [DOI: 10.20517/2394-5079.2022.80]
- Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, Bie P, Liu L, Wen T, Kuang M, Han G, Yan Z, Wang M, Liu R, Lu L, Ren Z, Zeng Z, 3 Liang P, Liang C, Chen M, Yan F, Wang W, Hou J, Ji Y, Yun J, Bai X, Cai D, Chen W, Chen Y, Cheng S, Dai C, Guo W, Guo Y, Hua B, Huang X, Jia W, Li Q, Li T, Li X, Li Y, Liang J, Ling C, Liu T, Liu X, Lu S, Lv G, Mao Y, Meng Z, Peng T, Ren W, Shi H, Shi G, Shi M, Song T, Tao K, Wang J, Wang K, Wang L, Wang X, Xiang B, Xing B, Xu J, Yang J, Yang Y, Ye S, Yin Z, Zeng Y, Zhang B, Zhang L, Zhang S, Zhang T, Zhang Y, Zhao M, Zhao Y, Zheng H, Zhou L, Zhu J, Zhu K, Shi Y, Xiao Y, Yang C, Wu Z, Dai Z, Cai J, Cai X, Shen F, Qin S, Teng G, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). Liver Cancer 2023; 12: 405-444 [PMID: 37901768 DOI: 10.1159/000530495]
- Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in 4 BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56: 412-418 [PMID: 21756858 DOI: 10.1016/j.jhep.2011.05.020]
- 5 Zhong JH, Ke Y, Wang YY, Li LQ. Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension. Gut 2015; 64: 520-521 [PMID: 25187522 DOI: 10.1136/gutjnl-2014-308139]
- Li Z, Tan C, Liu X, Feng Z, Li K. Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma 6 under antiviral therapy. Infect Agent Cancer 2022; 17: 56 [PMID: 36397089 DOI: 10.1186/s13027-022-00468-6]
- Nevola R, Ruocco R, Criscuolo L, Villani A, Alfano M, Beccia D, Imbriani S, Claar E, Cozzolino D, Sasso FC, Marrone A, Adinolfi LE, 7 Rinaldi L. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol 2023; 29: 1243-1260 [PMID: 36925456 DOI: 10.3748/wig.v29.i8.12431
- Kara W, Anna Mae D, Cynthia AM. Challenges and barriers in hepatocellular carcinoma (HCC) surveillance for patients with non-alcoholic 8 fatty liver disease (NAFLD). Hepatoma Res 2023; 9: 11 [DOI: 10.20517/2394-5079.2022.92]
- 9 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2022; 23: 1126-1240 [PMID: 36447411 DOI: 10.3348/kjr.2022.0822]
- Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, 10 Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344-1354 [PMID: 26361969 DOI: 10.1016/S1470-2045(15)00198-9]
- Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, 11 Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402: 1835-1847 [PMID: 37871608 DOI: 10.1016/S0140-6736(23)01796-8]
- Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, 12 Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 2022; 28: 1599-1611 [PMID: 35739268 DOI: 10.1038/s41591-022-01868-21
- Li L, Wu PS, Liang XM, Chen K, Zhang GL, Su QB, Huo RR, Xie RW, Huang S, Ma L, Zhong JH. Adjuvant immune checkpoint inhibitors 13 associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study. J Gastroenterol 2023; 58: 1043-1054 [PMID: 37452107 DOI: 10.1007/s00535-023-02018-2]
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu 14 J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905 [PMID: 32402160 DOI: 10.1056/NEJMoa1915745]
- Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, 15 Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022; 23: 995-1008 [PMID: 35798016 DOI: 10.1016/S1470-2045(22)00326-6]
- Massimo F, Mariacristina P, Michele M, Francesco Rosario Paolo I, Marianna C, Bruno C, Teresa Antonia S. Risk of hepatocellular carcinoma 16 development in long-term nucles(t)ide analog suppressed patients with chronic hepatitis B. Hepatoma Res 2023; 9: 3 [DOI: 10.20517/2394-5079.2022.51]
- 17 Zhou J, Wang FD, Li LQ, Li YJ, Wang SY, Chen EQ. Antiviral Therapy Favors a Lower Risk of Liver Cirrhosis in HBeAg-negative Chronic Hepatitis B with Normal Alanine Transaminase and HBV DNA Positivity. J Clin Transl Hepatol 2023; 11: 1465-1475 [PMID: 38161505 DOI: 10.14218/JCTH.2023.00272]
- Huang DQ, Hoang JK, Kamal R, Tsai PC, Toyoda H, Yeh ML, Yasuda S, Leong J, Maeda M, Huang CF, Won Jun D, Ishigami M, Tanaka Y, 18 Uojima H, Ogawa E, Abe H, Hsu YC, Tseng CH, Alsudaney M, Yang JD, Yoshimaru Y, Suzuki T, Liu JK, Landis C, Dai CY, Huang JF, Chuang WL, Schwartz M, Dan YY, Esquivel C, Bonham A, Yu ML, Nguyen MH. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma. J Clin Oncol 2024; JCO2300757 [PMID: 38175991



Zhong JH. Unanswered questions about adjuvant therapy

DOI: 10.1200/JCO.23.00757]

- Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J 19 Gastroenterol 2023; 29: 1054-1075 [PMID: 36844141 DOI: 10.3748/wjg.v29.i6.1054]
- Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, 20 Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1399-1410 [PMID: 38039993 DOI: 10.1016/S1470-2045(23)00469-2]



Boishideng® WJG https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

